Nuvation Bio (NUVB)
NYSE:NUVB
NUVB Stock Chart & Stats
$4.35
-$0.19(-5.85%)
At close: 4:00 PM EST
$4.35
-$0.19(-5.85%)
Day’s Range― - ―
52-Week Range$1.54 - $9.75
Previous CloseN/A
Volume977.37K
Average Volume (3M)4.94M
Market Cap
$1.49B
Enterprise Value$1.33B
Total Cash (Recent Filing)$529.21M
Total Debt (Recent Filing)$10.15M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
May 19, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding346,597,300
10 Day Avg. Volume4,229,657
30 Day Avg. Volume4,940,451
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)10.01
Price to Sales (P/S)48.65
P/FCF Ratio-17.61
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue21.14
Enterprise Value/Gross Profit24.41
Enterprise Value/Ebitda-6.79
Forecast
1Y Price Target
$12.00Price Target Upside175.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$186.90M
Bulls Say, Bears Say
Bulls Say
Clinical Development And Regulatory PathwayDurable Phase 2 responses for safusidenib, combined with plans for an accelerated registration strategy and upcoming data readouts plus a European filing, create multiple clinical and regulatory catalysts that could materially lift valuation if positive.
Collaborative LicensingAn exclusive ex-U.S. licensing collaboration with a major pharmaceutical partner expands international commercialization rights and brings upfront payments, milestone potential, and tiered royalties that bolster financial flexibility.
Commercial AdoptionIbtrozi's launch showed faster adoption than prior ROS1-targeted therapies with increasing patient starts across multiple lines, supporting stronger market penetration and upside to revenue expectations.
Bears Say
Clinical And Competitive RiskPipeline programs face material downside if proof-of-concept trials fail or if competitive pressures curb uptake, which could constrain growth and lead to shareholder dilution concerns.
Research Objectivity ConcernsPotential conflicts arise because the covering firm conducts business with companies it covers, which may undermine confidence in the objectivity of positive analyst research.
Treatment Discontinuation ImpactHigh treatment discontinuation driven by many patients initiating therapy in later lines could depress usage metrics and slow perceived momentum for commercial uptake.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $1.54 and its highest was $9.75 in the past 12 months.
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $1.49B.
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is May 19, 2026 which is in 55 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on Mar 02, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.089 by -$0.021.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is >-0.01.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 346,597,300 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.089. Following the earnings report the stock price went down -25.342%.
Which hedge fund is a major shareholder of Nuvation Bio?
Currently, no hedge funds are holding shares in NUVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvation Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (175.86% Upside)
$12.00 (175.86% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.15%
12-Months-Change
Fundamentals
Return on Equity
-57.48%
Trailing 12-Months
Asset Growth
10.02%
Trailing 12-Months
Company Description
Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
NUVB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a number of strong clinical and commercial progress points — U.S. approval of IBTROZI, rapid new patient starts (~6x faster vs. prior launches), compelling durability data (median DOR 50 months in TKI‑naive), broad payer access, strong cash position ($529.2M), and advancing pipeline programs (safusidenib Phase III initiation and a non‑pivotal cohort with potential accelerated pathway). Offsetting these positives are near‑term commercial headwinds: a mismatch between new patient starts and net product revenue due to an early mix skewed toward later‑line patients who discontinue quickly, rising gross‑to‑net (~25%), high operating costs (R&D $115.1M; SG&A $151.6M), a discontinued DDC candidate, and long timelines for pivotal readouts (safusidenib SIGMA readout expected 2029). Overall, the call projects long‑term upside driven by clinical differentiation and international partnerships while acknowledging short‑term revenue and execution uncertainties.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$12.00
▲(175.86% Upside)
Technical Analysis
Nektar Therapeutics
―
Precigen
―
Wave Life Sciences
―
Enliven Therapeutics
―
Praxis Precision Medicines
―
Ownership Overview
24.92% Insiders
16.53% Mutual Funds
19.53% Other Institutional Investors
29.72% Public Companies and Individual Investors